• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PTX
Click for more information
3.85% 5.0¢

PRESCIENT THERAPEUTICS LIMITED - Charts / Financials

Market Cap $40.26M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 01/05/2024 (20 minute delay) ?
Day
Open 5.2¢   Day High 5.2¢   Day Low 4.9¢
Daily Volume 440054
Bids   Sellers
Number Price Volume   Number Price Volume
7 4.9¢ 189208   1 5.0¢ 6566

Directors & Senior Management

Mr. Steven Yatomi-Clarke Chief Executive Officer, Managing Director, Executive Director
Ms. Melanie Jaye Leydin Chief Financial Officer, Company Secretary
Mr. Steven B. Engle Non-Executive Chairman of the Board
Dr. James A. Campbell Non-Executive Director
Dr. Allen James Ebens Non-Executive Director
Dr. Ellen Gwen Feigal Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
5.0¢ 		Change
-0.002(3.85%) 		Mkt cap ! $40.26M
Open High Low Value Volume
5.2¢ 5.2¢ 4.9¢ $21.91K 440.0K

Buyers (Bids)

No. Vol. Price($)
7 189208 4.9¢
 

Sellers (Offers)

Price($) Vol. No.
5.0¢ 6566 1
View Market Depth
Last trade - 15.43pm 01/05/2024 (20 minute delay) ?
Last
5.0¢ 		  Change
-0.002 ( 0.00 %)
Open High Low Volume
5.0¢ 5.0¢ 4.9¢ 73482
Last updated 15.59pm 01/05/2024 ?

Top Stories

Carnarvon revs up for revised Dorado Development

The Dorado discovery appears on again, with Carnarvon Energy announcing the JV completing a revision of the project’s design to optimise capital costs and accelerate FID by the end of 2024.
Lithium Universe ends the quarter charged up for Quebec Refinery roll-out Lithium Universe has closed off the March quarter with a new Chief Financial Officer and strategically located land anchored for its lithium refinery in Quebec, Canada.
Provident Aurum's off-market bid sends Sihayo shares soaring Small-cap mineral and gold explorer, Sihayo Gold (ASX:SIH) shares have soared, on news that the company has received intentions from Provident Aurum Pte to make an off-market takeover offer to acquire all shares of Sihayo Gold.
Recharged Prospects: 'Watts' on the horizon for copper & lithium The conversation goes much deeper that this title suggests - it explores everything from projections on aluminium & manganese, to what a Donald Trump government could mean for commodities markets.
Why Princeton Professor rates BlinkLab's autism & ADHD screening app In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and potential of BlinkLab's (ASX:BB1) AI-driven smartphone app, designed to screen for autism and ADHD.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.